SPHERE - Study of Perinatal, paediatric and adolescent Health : Epidemiological Research and Evaluation
Equipe constitutive du CERPOP, UMR1295, unité mixte de recherche Inserm – Université Toulouse III Paul Sabatier
Christine DAMASE-MICHEL •  chercheure


 

2023
  1. Balon M, Tessier S, Damase-Michel C, Cottin J, Lambert A, Thompson MA, Benevent J, Lacroix I. Adverse drug reactions in pregnant women: Do they differ from those in non-pregnant women of childbearing age? Therapie. 2023 Mar-Apr;78(2):165-173. doi: 10.1016/j.therap.2022.11.005.
  2. Benevent J, Araujo M, Karki S, Delarue-Hurault C, Waser J, Lacroix I, Tebeka S, Damase-Michel C. Risk of Hypertensive Disorders of Pregnancy in Women Treated With Serotonin-Norepinephrine Reuptake Inhibitors: A Comparative Study Using the EFEMERIS Database. J Clin Psychiatry. 2023 Jul 10;84(4):22m14734. doi: 10.4088/JCP.22m14734.
  3. Benevent J, Araujo M, Beau AB, Sicard D, Sommet A, Hurault-Delarue C, Lacroix I, Damase-Michel C. First trimester pregnancy exposure to fosfomycin and risk of major congenital anomaly: a comparative study in the EFEMERIS database. Infection. 2023 Feb;51(1):137-146. doi: 10.1007/s15010-022-01861-4.
  4. Saint-Lary L, Benevent J, Damase-Michel C, Vayssière C, Leroy V, Sommet A. Adverse perinatal outcomes associated with prenatal exposure to protease-inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based antiretroviral combinations in pregnant women with HIV infection: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2023 Jan 30;23(1):80. doi: 10.1186/s12884-023-05347-5.
  5. Lee SI,Hanley S, Vowles Z, Plachcinski R, Moss N, Singh M, Gale C, Fagbamigbe AF, Azcoaga-Lorenzo A, Subramanian A, Taylor B, Nelson-Piercy C, Damase-Michel C, Yau C, McCowan C, O'Reilly D, Santorelli G, Dolk H, Hope H, Phillips K, Abel KM, Eastwood KA, Kent L, Locock L, Loane M, Mhereeg M, Brocklehurst P, McCann S, Brophy S, Wambua S, Hemali Sudasinghe SPB, Thangaratinam S, Nirantharakumar K, Black M; MuM-PreDiCT Group. The development of a core outcome set for studies of pregnant women with multimorbidity. BMC Med. 2023 Aug 21;21(1):314. doi: 10.1186/s12916-023-03013-3.
  6. Lee SI, Hope H, O'Reilly D, Kent L, Santorelli G, Subramanian A, Moss N, Azcoaga-Lorenzo A, Fagbamigbe AF, Nelson-Piercy C, Yau C, McCowan C, Kennedy JI, Phillips K, Singh M, Mhereeg M, Cockburn N, Brocklehurst P, Plachcinski R, Riley RD, Thangaratinam S, Brophy S, Hemali Sudasinghe SPB, Agrawal U, Vowles Z, Abel KM, Nirantharakumar K, Black M, Eastwood KA; MuM-PreDiCT (Damase-Michel C, collaborator). Maternal and child outcomes for pregnant women with pre-existing multiple long-term conditions: protocol for an observational study in the UK. BMJ Open. 2023 Feb 24;13(2):e068718. doi: 10.1136/bmjopen-2022-068718.
  7. Larcin L, Karakaya G, Rygaert X, Van Wilder P, Lamy C, Demyttenaere B, Damase-Michel C, Kirakoya-Samadoulougou F. Trends and regional variations in prescriptions dispensed to stimulate uterine contractions at the end of pregnancy in Belgium: A community-based study from 2003 to 2018. Pharmacoepidemiol Drug Saf. 2023 Feb;32(2):216-224. doi: 10.1002/pds.5558.
  8. Subramanian A, Azcoaga-Lorenzo A, Anand A, Phillips K, Lee SI, Cockburn N, Fagbamigbe AF, Damase-Michel C, Yau C, McCowan C, O'Reilly D, Santorelli G, Hope H, Kennedy JI, Abel KM, Eastwood KA, Locock L, Black M, Loane M, Moss N, Plachcinski R, Thangaratinam S, Brophy S, Agrawal U, Vowles Z, Brocklehurst P, Dolk H, Nelson-Piercy C, Nirantharakumar K; MuM-PreDiCT Group. Polypharmacy during pregnancy and associated risk factors: a retrospective analysis of 577 medication exposures among 1.5 million pregnancies in the UK, 2000-2019. BMC Med. 2023 Jan 16;21(1):21. doi: 10.1186/s12916-022-02722-5.
2023 publications cliniques
  1. Anand A, Phillips K, Subramanian A, Lee SI, Wang Z, McCowan R, Agrawal U, Fagbamigbe AF, Nelson-Piercy C, Brocklehurst P, Damase-Michel C, Loane M, Nirantharakumar K, Azcoaga-Lorenzo A; MuM-PreDiCT Group. Prevalence of polypharmacy in pregnancy: a systematic review. BMJ Open. 2023 Mar 6;13(3):e067585. doi: 10.1136/bmjopen-2022-067585.
  2. Faurie I, Harroch E, Scotto d'Apollonia C, Corte S, Arcari C, Mohara C, Barthelemy C, Fabre MH, Boussac M, Damase-Michel C, Almudever B, Croity-Belz S, Brefel-Courbon C. Impact of therapeutic education on the evolution of social representations of medication in patients with Parkinson's disease: A quantitative and qualitative study (ETPARK REMED). Rev Neurol (Paris). 2023 Aug 24:S0035-3787(23)01004-4. doi: 10.1016/j.neurol.2023.03.026. Epub ahead of print.
2022
  1. Araujo M, Hurault-Delarue C, Sommet A, Damase-Michel C, Lacroix I. Topical sertaconazole during pregnancy and risk of adverse pregnancy outcome and major congenital anomalies: Comparative study in the EFEMERIS database. Mycoses. 2022 Apr;65(4):481-489. doi: 10.1111/myc.13422.
  2. Benevent J, Hurault-Delarue C, Araujo M, Revet A, Sommet A, Lacroix I, Damase-Michel C. Prenatal Drug Exposure in Children With a History of Neuropsychiatric Care: A Nested Case-Control Study. Front Psychiatry. 2022 Mar 22;13:795890. doi: 10.3389/fpsyt.2022.795890.
  3. Dolk H, Damase-Michel C, Morris JK, Loane M. COVID-19 in pregnancy-what study designs can we use to assess the risk of congenital anomalies in relation to COVID-19 disease, treatment and vaccination? P aediatr Perinat Epidemiol. 2022 Jul;36(4):493-507. doi: 10.1111/ppe.12840.
  4. Jordan S, Bromley R, Damase-Michel C, Given J, Komninou S, Loane M, Marfell N, Dolk H. Breastfeeding, pregnancy, medicines, neurodevelopment, and population databases: the information desert. Int Breastfeed J. 2022 Aug 2;17(1):55. doi: 10.1186/s13006-022-00494-5.
  5. Lee SI, Azcoaga-Lorenzo A, Agrawal U, Kennedy JI, Fagbamigbe AF, Hope H, Subramanian A, Anand A, Taylor B, Nelson-Piercy C, Damase-Michel C, Yau C, Crowe F, Santorelli G, Eastwood KA, Vowles Z, Loane M, Moss N, Brocklehurst P, Plachcinski R, Thangaratinam S, Black M, O'Reilly D, Abel KM, Brophy S, Nirantharakumar K, McCowan C; MuM-PreDiCT Group. Epidemiology of pre-existing multimorbidity in pregnant women in the UK in 2018: a population-based cross-sectional study. BMC Pregnancy Childbirth. 2022 Feb 11;22(1):120. doi: 10.1186/s12884-022-04442-3.
  6. Thurin NH, Pajouheshnia R, Roberto G, Dodd C, Hyeraci G, Bartolini C, Paoletti O, Nordeng H, Wallach-Kildemoes H, Ehrenstein V, Dudukina E, MacDonald T, De Paoli G, Loane M, Damase-Michel C, Beau AB, Droz-Perroteau C, Lassalle R, Bergman J, Swart K, Schink T, Cavero-Carbonell C, Barrachina-Bonet L, Gomez-Lumbreras A, Giner-Soriano M, Aragón M, Neville AJ, Puccini A, Pierini A, Ientile V, Trifirò G, Rissmann A, Leinonen MK, Martikainen V, Jordan S, Thayer D, Scanlon I, Georgiou ME, Cunnington M, Swertz M, Sturkenboom M, Gini R. From Inception to ConcePTION: Genesis of a Network to Support Better Monitoring and Communication of Medication Safety During Pregnancy and Breastfeeding. Clin Pharmacol Ther. 2022 Jan;111(1):321-331. doi: 10.1002/cpt.2476.
  7. Vabre C, Araujo M, Damase-Michel C, Hurault-Delarue C, Lacroix I. Initial data on the safety of metopimazine during pregnancy and the risk of major birth defects and pregnancy loss - An observational study using the EFEMERIS database. Therapie. 2022 Jul-Aug;77(4):405-412. doi: 10.1016/j.therap.2021.09.006.
  8. Wood ME, Lupattelli A, Palmsten K, Bandoli G, Hurault-Delarue C, Damase-Michel C, Chambers CD, Nordeng HME, van Gelder MMHJ. Longitudinal Methods for Modeling Exposures in Pharmacoepidemiologic Studies in Pregnancy. Epidemiol Rev. 2022 Jan 14;43(1):130-146. doi: 10.1093/epirev/mxab002.
2021
  1. Araujo M, Hurault-Delarue C, Sommet A, Damase-Michel C, Benevent J, Lacroix I. Drug prescriptions in French pregnant women between 2015 and 2016: A study in the EGB database. Therapie. 2021 May-Jun;76(3):239-247. doi: 10.1016/j.therap.2020.07.002.
  2. Araujo M, Vabre C, Benevent J, Sommet A, Damase-Michel C, Hurault-Delarue C, Lacroix I.Risk of Pregnancy Termination and Congenital Anomalies After Domperidone Exposure: A Study in the EFEMERIS Database. Drug Saf. 2021 Jul;44(7):787-796.. doi: 10.1007/s40264-021-01077-9.
  3. Blotière PO, Damase-Michel C, Weill A, Maura G. Dispensing of Potentially Harmful Prescription Drugs in 1.8 Million Pregnant Women in France: A Nationwide Study Based on Two Risk Classification Systems. Drug Saf. 2021 Dec;44(12):1323-1339. doi: 10.1007/s40264-021-01117-4.
  4. Hurault-Delarue C, Araujo M, Vabre C, Benevent J, Damase-Michel C, Lacroix I. What changes in prescription patterns of antiemetic medications in pregnant women in France ? Fundam Clin Pharmacol. 2021 Dec;35(6):1159-1167. . doi: 10.1111/fcp.12681.
  5. Lacroix I, Hurault-Delarue C, Viard D, Revol B, Chaalel L, Damase-Michel C. Use of triptans during pregnancy? With caution! Therapie. 2021 Sep-Oct;76(5):477-478. doi: 10.1016/j.therap.2019.12.007.
  6. Larcin L, Lona M, Karakaya G, Van Espen A, Damase-Michel C, Kirakoya-Samadoulougou F. Using administrative healthcare database records to study trends in prescribed medication dispensed during pregnancy in Belgium from 2003 to 2017. Pharmacoepidemiol Drug Saf. 2021 Sep;30(9):1224-1232. doi: 10.1002/pds.5299.
2020
  1. Araujo M, Hurault-Delarue C, Sommet A, Damase-Michel C, Benevent J, Lacroix I. Drug prescriptions in French pregnant women between 2015 and 2016: A study in the EGB database. Therapie. 2020 Jul 10:S0040-5957(20)30122-0. doi: 10.1016/j.therap.2020.07.002.
  2. Bénard-Laribière A, Pambrun E, Sutter-Dallay AL, Gautier S, Hurault-Delarue C, Damase-Michel C, Lacroix I, Pariente A. Impact of pregnancy on antidepressant treatment course: a population-based comparative cohort study in France. Arch Womens Ment Health. 2020 May 1 doi: 10.1007/s00737-020-01033-z.
  3. Lacroix I, Benevent J, Damase-Michel C. Chloroquine and hydroxychloroquine during pregnancy: What do we know? Therapie. 2020 May 11:S0040-5957(20)30093-7. doi: 10.1016/j.therap.2020.05.004.
2019
  1. Araujo M, Hurault-Delarue C, Bouilhac C, Petiot P, Benevent  J, Vayssière C, Vidal S, Montastruc JL, Damase-Michel  C, Lacroix  I. Non-steroidal anti-inflammatory drug prescriptions from the 6th month of pregnancy: impact of advice from health authorities. Fundam Clin Pharmacol. 2019. 33(5):581–588. doi:10.1111/fcp.12460
  2. Benevent J, Araujo M, Hurault-Delarue C, Montastruc JL, Sommet A, Lacroix I, Damase-Michel C. Pharmacoepidemiology in pregnancy. Therapie. 2019. 74(2):289-300. doi: 10.1016/j.therap.2018.11.014.
  3. Benevent J, Hurault-Delarue C, Araujo M, Montastruc F, Montastruc JL, Lacroix I, Damase-Michel C. Higher intake of medications for digestive disorders in children prenatally exposed to drugs with atropinic properties. Fundam Clin Pharmacol. 2019. 33(3):314-326. doi: 10.1111/fcp.12428.
  4. Benevent J, Hurault-Delarue C, Araujo M, Montastruc JL, Lacroix I, Damase-Michel C. POMME: The New Cohort to Evaluate Long-Term Effects After Prenatal Medicine Exposure.Drug Saf. 2019. 42(1):45-54. doi: 10.1007/s40264-018-0712-9.
  5. Charlton R, Damase-Michel C, Hurault-Delarue C, Gini R, Loane M, Pierini A, Puccini  A, Neville  A, Snowball  J, K Morris  J. EUROmediSAFE consortium. Did advice on the prescription of sodium valproate reduce prescriptions to women? An observational study in three European countries between 2007 and 2016. Pharmacoepidemiol Drug Saf. 2019. 28(11):1519–1528. doi:10.1002/pds.4881.
  6. Hurault-Delarue C, Lacroix I, Bénard-Laribière A, Montastruc JL, Pariente A, Damase-Michel C. Antidepressants during pregnancy: a French drug utilisation study in EFEMERIS cohort. Eur Arch Psychiatry Clin Neurosci. Eur Arch Psychiatry Clin Neurosci.2019. 269(7):841–849. doi:10.1007/s00406-018-0906-2
  7. Hurault-Delarue C, Morris JK, Charlton R, Gini  R, Loane  M, Pierini  A, Puccini  A, Neville A , Snowball J, Damase-Michel C. EUROmediSAFE consortium. Prescription of antiepileptic medicines including valproate in pregnant women: A study in three European countries. Pharmacoepidemiol Drug Saf. 2019. 28(11):1510–1518. doi:10.1002/pds.4897.
  8. Lacroix I, Hurault-Delarue C, Viard D, Revol B, Chaalel L, Damase-Michel C. Use of triptans during pregnancy? With caution! 2019 Dec 20]. Therapie. 2019;S0040-5957(19)30189-1. doi:10.1016/j.therap.2019.12.007.
  9. Montastruc JL, Montastruc F, Benevent J, Lacroix I, Durrieu G, Du Plantier JM, Bagheri H, Sommet A, Damase-Michel C. Tintin in the Land of Drugs: A pharmacological, pharmacovigilance approach. Therapie. 2019. 74(3):445-447. doi: 10.1016/j.therap.2019.01.002.